How Fast Does Retatrutide Work? A Week-by-Week Timeline

When will I see results on retatrutide?

In the trials, most of retatrutide’s weight loss arrived after the dose-escalation phase — not in the first few weeks. Appetite changes can show up early, within the first month at the 2 mg starting dose, but the scale moves slowly at first and then accelerates once people reach the higher maintenance doses. The headline figures everyone quotes — around 24% at 48 weeks in Phase 2 and roughly 28% at 68 to 80 weeks in Phase 3 — are the endpoints of long trials, not what you would expect at week 3 or week 12.

One caveat before the milestones, and it matters: every number below is a group mean measured in a clinical trial, not a guaranteed individual result and not a personal anecdote. Retatrutide (sometimes shortened to “reta” in patient communities) is investigational, so there are no real-world before-and-after timelines — only trial-reported averages. For the complete, fully referenced version of this trajectory, see our full weight-loss timeline.

The dose schedule these numbers ride on

Retatrutide’s trajectory is inseparable from how the dose climbs. The Phase 3 TRIUMPH program used a five-step escalation, described by Giblin et al. in Diabetes, Obesity and Metabolism (2026):

Each step lasts about four weeks, and a permanent dose reduction is allowed if gastrointestinal side effects become hard to tolerate. Because the full 12 mg dose is not reached until roughly week 17, the first four months are mostly ramp-up. We unpack the reasoning in dose escalation explained.

Weeks 1-3: starting at 2 mg

The first three weeks are the 2 mg introductory dose — the lowest rung, chosen for tolerability rather than for weight loss. What participants typically notice first is not the scale but appetite: smaller portions, earlier fullness, less food “noise.” Any weight change at this point is modest, and some of it is fluid and gut-content shifts rather than fat loss. This is the expected pattern, not a sign the drug is failing — the trials were never designed to produce dramatic three-week numbers.

Weeks 4-8: the 4 mg step

At week 5 the dose doubles to 4 mg. Appetite suppression usually becomes more consistent, and by the end of this window the downward trend on the scale is clearer. Gastrointestinal side effects — nausea, loose stools, the occasional bout of vomiting — are most likely during these dose increases and are usually mild to moderate. Worth remembering: 4 mg is a target maintenance dose for some participants, not just a stepping stone. In TRIUMPH-1, the 4 mg arm still finished at -19.0% weight loss at 80 weeks (Eli Lilly press release). So even the “low” dose is potent, given enough time.

Weeks 9-12: the three-month mark (6 mg)

By around 10 to 12 weeks, participants have stepped up to 6 mg — still only half the top dose. Here is the honest answer to “what are my 12-week results”: the pivotal trials do not report a formal 12-week weight-loss endpoint, so any specific “12-week number” circulating online is not from the retatrutide trials themselves. What the published curves show is that at three months a participant is still escalating and has captured only an early fraction of the eventual total. The loss is real and building, but it is well short of the 24 to 28 percent figures that come much later. Expect steady, unglamorous progress here — the acceleration is still ahead.

Weeks 13-16: the 9 mg step

The dose rises to 9 mg, the second-highest level. In the completed trials, 9 mg is genuinely powerful on its own — TRIUMPH-1 reported -25.9% weight loss at 80 weeks for the 9 mg arm (Eli Lilly press release), and the type 2 diabetes trial TRANSCEND-T2D-1 showed -13.9% at 40 weeks for 9 mg (The Lancet, 2026). During weeks 13 to 16, though, these are still early days at this dose; the numbers above are long-run endpoints, not what the scale reads at four months.

Week 17 onward: reaching 12 mg maintenance

From roughly week 17, participants on the top-dose arm reach 12 mg and hold there. This is where the trajectory does most of its work. Escalation is over, appetite suppression is at full strength, and the weekly curve keeps sloping downward for many months — it does not flatten at four or six months. The single most important thing to understand about retatrutide’s timeline is this: the biggest share of weight loss accumulates during maintenance, not during escalation. A three-month or four-month check-in captures the ramp, not the payoff.

The endpoint milestones: where the trajectory lands

Because the trials report their primary results at fixed endpoints, those are the numbers we can state with confidence. All figures below are 12 mg group means:

Two things stand out. First, these are three separate trials in different populations, so they are not one continuous curve — but within each study the loss was still building at the measured endpoint rather than flattening, and the later, longer trials land higher than the 48-week Phase 2 read. A separate Phase 2 diabetes read (Rosenstock et al., The Lancet, 2023) showed -16.9% at week 36, consistent with loss that keeps accruing past eight months rather than stalling. Second, TRIUMPH-1’s headline depends on how you count: -28.3% is the efficacy estimand (the result while people are actually on treatment), while the treatment-regimen estimand — which folds in participants who stopped the drug — was -25.0% (Eli Lilly). Both are legitimate; they answer slightly different questions.

For how these percentages sit against tirzepatide, semaglutide, and the rest of the class, see our weight-loss outcomes overview.

Quick FAQ

How much weight will I lose in the first month? The trials do not publish a one-month group mean, and any honest figure would be small — month one is the 2 mg starting dose. Early on, appetite change is a more reliable signal than the scale.

Is three months enough to judge whether it is working? By design, three months is still the escalation phase (around 6 mg). Most of the measured loss arrives after reaching 12 mg maintenance near week 17, so a three-month readout understates the full trajectory.

Do the results plateau? Not by the points the trials measured. Within each retatrutide study, weight loss was still increasing at its endpoint — week 48 in Phase 2, week 68 in TRIUMPH-4, and week 80 in TRIUMPH-1.

The honest bottom line

Retatrutide is an investigational drug. It is not approved by the FDA or any regulator as of July 2026, and nothing here is medical advice or a promise of personal results — every figure is a trial-measured average from a specific study population. If you are trying to picture a realistic timeline, the data tell a consistent story: patience through the escalation weeks, with the largest returns arriving later, during maintenance dosing.